BIND Biosciences Initiates Phase 1 Clinical Study Of BIND-014, A First-In-Class Targeted Nanoparticle Therapeutic For Cancer
"Initiating clinical development of BIND-014, our most advanced product candidate, is an important milestone for BIND. Preclinical studies demonstrate the ability of BIND's targeted nanoparticle technology to enhance the trafficking of cytotoxic agents to cancer cells and increase efficacy, which, if confirmed in human trials, has the potential to improve outcomes for patients," said Scott Minick, President and Chief Executive Officer of BIND Biosciences. "By precisely targeting and controlling the exposure of drugs to disease sites, BIND's Medicinal Nanoengineering platform has the potential to produce drug candidates across an array of therapeutic areas including oncology, inflammatory disease and cardiovascular disorders."
The Phase 1 study has an ascending, intravenous dose design to assess the safety, tolerability and pharmacokinetics of BIND-014 in approximately 30 cancer patients. The primary objective of the study is to determine the maximum tolerated dose of BIND-014 and to assess preliminary evidence of antitumor activity. Patients are currently being screened for eligibility in this clinical trial, which is being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona in collaboration with the Translational Genomics Research Institute (TGen) and the Scottsdale Healthcare Research Institute.
"The preclinical profile of BIND-014 demonstrating activity against many types of very common cancers is very encouraging," commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician in Chief and Distinguished Professor at TGen and Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. "My colleagues and I are excited to work with BIND in the clinical development of BIND-014 for the benefit of our patients."
BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent docetaxel (Taxotere), which is approved in major cancer indications including breast, prostate and lung. BIND-014 is targeted to prostate-specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to 20 times more docetaxel to tumors than an equivalent dose of Taxotere. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in cancer patients. This first of its kind human study stems from BIND's previously published non-human studies in several peer-reviewed scientific journals. The development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).
Virginia G. Piper Cancer Center at Scottsdale Healthcare
Translational Genomics Research Institute (TGen)
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Biosciences, BIND. "BIND Biosciences Initiates Phase 1 Clinical Study Of BIND-014, A First-In-Class Targeted Nanoparticle Therapeutic For Cancer." Medical News Today. MediLexicon, Intl., 10 Jan. 2011. Web.
23 Apr. 2017. <http://www.medicalnewstoday.com/releases/213241.php>
Biosciences, B. (2011, January 10). "BIND Biosciences Initiates Phase 1 Clinical Study Of BIND-014, A First-In-Class Targeted Nanoparticle Therapeutic For Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.